Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: A network metaanalysis:Efficacy of 7 targeted therapies for AHCC

Medicine (United States)

Volumn 95, Issue 49, 2016, Pages e5591-

  Niu, Meng ^a   Hong, Duo ^a   Ma, Teng Chuang ^a   Chen, Xiao Wei ^a   Han, Jin Hang ^a   Sun, Jun ^a   Xu, Ke ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Advanced hepatocellular carcinoma; Complete response; Partial response; Placebo; Progressive disease; Stable disease; Targeted drug

Indexed keywords

BRIVANIB; ERLOTINIB; EVEROLIMUS; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TIVANTINIB; CARBANILAMIDE DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COCHRANE LIBRARY; DISEASE CONTROL; DRUG EFFICACY; EMBASE; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; LIVER NEOPLASMS; MALE; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION;

ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85007505051     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005591     Document Type: Article

References (53)

1. Ge S, Huang D. Systemic therapies for hepatocellular carcinoma. Drug Discov Ther 2015;9:352-62.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73. e1261.
3. Huang YT, Yang HI, Liu J, et al. Mediation analysis of hepatitis b and c in relation to hepatocellular carcinoma risk. Epidemiology 2016;27:14-20.
4. Flemming JA, Yang JD, Vittinghoff E, et al. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the adress-hcc risk model. Cancer 2014;120:3485-93.
5. Moray G, Kirnap M, Akdur A, et al. Outcomes of patients with hepatocellular carcinoma after liver transplant. Exp Clin Transplant 2015;13(Suppl 3):30-2.
6. Chu KK, Cheung TT. Update in management of hepatocellular carcinoma in eastern population. World J Hepatol 2015;7:1562-71.
7. Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early hcc with eob-mri: Experiences and current consensus. Liver Cancer 2014;3:97-107.
8. Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-11.
9. Jiang W, Zeng ZC. Is it time to adopt external beam radiotherapy in the nccn guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma? Oncology 2013;84(Suppl 1):69-74.
10. Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: new advances and challenges. World J Hepatol 2015;7:787-98.
11. Hung CH, Chiu YC, Chen CH, et al. Micrornas in hepatocellular carcinoma: Carcinogenesis, progression, and therapeutic target. Biomed Res Int 2014;2014:486407.
12. Mazzoccoli G, Miele L, Oben J, et al. Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib. Curr Drug Targets 2015;17:783-99.
13. Lee JH, Chung YH, Kim JA, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013;119:136-42.
14. Lu S, Torok HP, Gallmeier E, et al. Tivantinib (arq 197) affects the apoptotic and proliferative machinery downstream of c-met: Role of mcl-1, bcl-xl and cyclin b1. Oncotarget 2015;6:22167-78.
15. Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011;117:5094-102.
16. Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel vegfr2 inhibitors. Ann Transl Med 2014;2:123.
17. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase ii study. J Clin Oncol 2009;27:3027-35.
18. Kaseb AO, Morris JS, Iwasaki M, et al. Phase ii trial of bevacizumab and erlotinib asa second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther 2016;9:773-80.
19. Lebioda A, Gasche D, Dippel FW, et al. Relevanceofindirect comparisons in the german early benefit assessment and in comparison to hta processes in england, france and scotland. Health Econ Rev 2014;4:31.
20. Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
21. Chung JH, Lee SW. Assessing the quality of randomized controlled urological trials conducted by korean medical institutions. Korean J Urol 2013;54:289-96.
22. Tu YK, Needleman I, Chambrone L, et al. Abayesiannetworkmeta-analysis oncomparisonsofenamelmatrixderivatives, guidedtissueregenerationand their combination therapies. J Clin Periodontol 2012;39:303-14.
23. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
24. Schultz MA, Daly B. Differences and similarities in nurses' perceptions of intensive care nursing and non-intensive care nursing. Focus Crit Care 1989;16:465-71.
25. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in stata. PLoS One 2013;8:e76654.
26. Zhu AX, Rosmorduc O, Evans TR, et al. Search: a phase iii, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559-66.
27. Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (reach): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-70.
28. Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the evolve-1 randomized clinical trial. JAMA 2014;312:57-67.
29. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55-63.
30. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase iii brisk-ps study. J Clin Oncol 2013;31:3509-16.
31. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase iii brisk-fl study. J Clin Oncol 2013;31:3517-24.
32. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase iii trial. J Clin Oncol 2013;31:4067-75.
33. Berretta M, Di Benedetto F, Dal Maso L, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013;24:212-8.
34. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
35. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008;112:250-9.
36. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
37. Fala L. Cyramza (ramucirumab) approved for the treatment of advanced gastric cancer and metastatic non-small-cell lung cancer. Am Health Drug Benefits 2015;8((Spec Feature)):49-53.
38. Qiu MZ, Xu RH. The progress of targeted therapy in advanced gastric cancer. Biomark Res 2013;1:32.
39. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009;23:289-304.
40. Pu K, Yuan L, Chen L, et al. Identification of vegfr2-binding peptides using high throughput bacterial display methods and functional assessment. Curr Cancer Drug Targets 2015;15:158-70.
41. Spratlin JL, Cohen RB, Eadens M, et al. Phase i pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immuno-globulin g1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7.
42. Ueda S, Satoh T, Gotoh M, et al. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist 2015;20: 493-4.
43. Quintela-Fandino M, Le Tourneau C, Duran I, et al. Phase i combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacoki-netic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther 2010;9:751-60.
44. Wang SB, Lei KJ, Liu JP, et al. Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: a case report and literature review. Oncol Lett 2015;10:954-6.
45. Gu FM, Li QL, Gao Q, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking stat3. World J Gastroenterol 2011;17:3922-32.
46. Yuan H, Li AJ, Ma SL, et al. Inhibition of autophagy significantly enhances combination therapy with sorafenib and hdac inhibitors for human hepatoma cells. World J Gastroenterol 2014;20: 4953-62.
47. Lind JS, Dingemans AM, Groen HJ, et al. A multicenter phase ii study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:3078-87.
48. Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate ((s)-((r)-1-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2, 1-f][1, 2, 4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel pro-drug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (bms-540215). J Med Chem 2008;51:1976-80.
49. Bhide RS, Lombardo LJ, Hunt JT, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010;9:369-78.
50. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14:6146-53.
51. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase ii, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-80.
52. Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase ii study. Ann Oncol 2011;22:1528-34.
53. Spigel DR, Burris HA3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase ii trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2582-9.